Aerpio Therapeutics raises $27 million for novel diabetic macular edema drug
This article was originally published in Scrip
Aerpio Therapeutics, the Cincinnati, Ohio-based company, raised $27 million in a Series A financing round to fund its first-in-class Tie2 receptor activator AKB-9778 through 2014 when the company plans to complete a Phase II clinical trial in the treatment of diabetic macular edema (DME).
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.